multiple myeloma epidemiology forecast insight
DelveInsight’s ‘Multiple Myeloma Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the disease, historical and forecasted MM epidemiology in the 8MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
- China
Study Period: 2017–2034
Multiple Myeloma (MM) Understanding
According to the American Cancer Society, Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system. Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States. MM is slightly more prevalent in males compared to females. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people and most frequently diagnosed among people aged 65–74.
Approximately 95% of cases are diagnosed at a distant stage or metastatic stage and 5-year relative survival rate for this stage is around 53%. Most of the researchers are unaware of the exact cause of multiple myeloma. However, they have made progress in understanding how certain changes in DNA can make plasma cells become cancerous. DNA is the chemical that transfers the instructions for nearly everything the cells do in the body. Patients with active myeloma generally receive treatment aimed at reducing or at least providing relief from symptoms and reducing the number of myeloma cells in the bone marrow.
Multiple Myeloma Diagnosis
Multiple myeloma is often diagnosed based on tests, the patient’s symptoms and the doctor’s physical exam of the patient. A diagnosis of multiple myeloma requires either:
1. A plasma cell tumor (proven by biopsy) or at least 10% plasma cells in the bone marrow
2. At least one of the following:
- High blood calcium level
- Poor kidney function
- Low red blood cell counts (anemia)
- Holes in the bones from tumor found on imaging studies (CT, MRI, PET scan)
- Increase in one type of light chain in the blood so that one type is 100 times more common than the other
- 60% or more plasma cells in the bone marrow
Epidemiology Perspective by DelveInsight
The Multiple Myeloma epidemiology division provides insights about historical and current patient pool and forecasted trends for each eight major countries. The Multiple Myeloma epidemiology data are studied through Multiple Myeloma possible division to give a better understanding of the Disease scenario in the 8MM.
The disease epidemiology covered in the report provides historical as well as forecasted Multiple Myeloma epidemiology [segmented as Total Incidence of Multiple Myeloma, Total Symptomatic Cases of Multiple Myeloma, Total Incident Cases of Multiple Myeloma Segmented by Gender, Total Diagnosed cases of Multiple Myeloma by Age Distribution, Total Cases of Multiple Myeloma by Line of Treatment] scenario of Multiple Myeloma in the 8MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2017 to 2034.
Multiple Myeloma Detailed Epidemiology Segmentation
- In the year 2020, the total incident case of Multiple Myeloma was 91,693 cases in the 8MM. The United States, in 2020, accounted for 32,270 cases (the highest number), which will probably rise by the year 2034. Among the EU-5 countries, the highest number of incident cases of Multiple Myeloma in the year 2020, was in Germany. In China, the total number of incident cases of Multiple Myeloma was 21,116 in 2020, and this number is expected to rise throughout the forecast period.
- The overall number of symptomatic cases of Multiple Myeloma in the 8MM was 80,715, and these cases are expected to rise by 2034.
- Males are more likely to develop Multiple Myeloma than females (about 55 percent of cases). When it comes to age-specific Multiple Myeloma cases, the age group 65–74 years has by far the most, followed by 75–84 years and 55–64 years.
- In the 8MM, the total cases of Multiple Myeloma by treatment line were 23,581 cases for frontline transplant-eligible patients, 49,699 cases for frontline transplant-ineligible patients, 44,955 cases for second-line patients, 23,498 cases for third-line patients, and 10,236 cases for fourth-line plus patients, in the year 2020.
Scope of the Report
- The Multiple Myeloma report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
- The Multiple Myeloma Report and Model provide an overview of the risk factors and global trends of MM in the eight major markets (8MM: United States, Germany, France, Italy, Spain, and the United Kingdom, Japan, and China).
- The report provides insight about the historical and forecasted patient pool of Multiple Myeloma in eight major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan and China, and China.
- The report helps to recognize the growth opportunities in the 8MM with respect to the patient population.
- The report assesses the disease risk and burden and highlights the unmet needs of Multiple Myeloma.
- The report provides the segmentation of the Multiple Myeloma epidemiology by total Incidence of cases in the 8MM.
- The report provides the segmentation of the Multiple Myeloma epidemiology by total symptomatic cases in the 8MM.
- The report provides the segmentation of the Multiple Myeloma epidemiology by Age and Gender in the 8MM.
- The report provides the segmentation of the Multiple Myeloma epidemiology by Line-wise treated Patient Pool in the 8MM.
Report Highlights
- 10-Year Forecast of Multiple Myeloma epidemiology
- 8MM Coverage
- Total Incident Cases of Multiple Myeloma in the 8MM
- Total Symptomatic Incident Cases of Multiple Myeloma in the 8MM
- Incident Cases of Multiple Myeloma according to segmentation: Age, and Gender
- Treated cases of Multiple Myeloma
KOL-Views
We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over Multiple Myeloma scenario of the indications.
Key Questions Answered
- What will be the growth opportunities in the 8MM with respect to the patient population pertaining to Multiple Myeloma?
- What are the key findings pertaining to the Multiple Myeloma epidemiology across the 8MM and which country will have the highest number of patients during the study period (2017–2034)?
- What would be the total number of patients of Multiple Myeloma across the 8MM during the study period (2017–2034)?
- Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2034)?
- At what CAGR the patient population is expected to grow in the 8MM during the study period (2017–2034)?
- What are the various recent and upcoming events which are expected to improve the diagnosis of Multiple Myeloma?
Reasons to buy
The Multiple Myeloma Epidemiology report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the global Multiple Myeloma market
- Quantify patient populations in the global Multiple Myeloma market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Multiple Myeloma therapeutics in each of the markets covered
- Understand the magnitude of Multiple Myeloma population by its severity
- The Multiple Myeloma epidemiology report and model were written and developed by Masters and PhD level epidemiologists
- The Multiple Myeloma Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
